Enjoy complimentary customisation on priority with our Enterprise License!
According to bladder cancer therapeutics industry insights, the global bladder cancer therapeutics market will grow at a CAGR of close to 5% during the forecast period. The availability of targeted therapy will be one of the major factors driving the growth prospects for the market until the end of 2021. The advancements in drug targeting techniques have enabled doctors to administer drugs directly into the bladder having tumors. This, in turn, will help in avoiding the side effects of these drugs on healthy cells. With a better understanding of tumor, immunology scientists can also now develop new drugs targeted at cancer cells. TECENTRIQ and OPDIVO are the PD-L1 inhibitors recently approved by the US FDA for the treatment of urothelial carcinoma.
One of the effective procedures for the diagnosis of bladder cancer, cystoscopy, involves the use of a long thin tube called cystoscope. This helps the urologist to extract a small piece of the abnormal tissue and send it to the pathologists for examination. With the emergence of effective diagnostic tools such as the flexible cystoscope, urologists will prefer cystoscopy since it can be easily performed in the outpatient department. This emergence of effective diagnostic tools will be one of the major trends that will gain traction in the bladder cancer therapeutics market during the next four years.
The bladder cancer therapeutics market consists of a few vendors who concentrate on improving their profit margins through direct sales and through distributor channels. The competition among the players in this market space is mainly based on factors including emerging indications or applications and collaborations. To improve their market positions, the vendors are increasingly focusing on the development of new products and gaining approvals. To develop new products, a few vendors are also concentrating on partnering with other market players.
Key vendors in this market are
Other prominent vendors in the market include Accord Healthcare, AstraZeneca, Bedford Lab, Merck, and Sanofi.
Chemotherapy is mainly used for the treatment of invasive cancer and relieve bladder cancer symptoms by declining the rate at which cancer spreads. This market study estimates that the chemotherapy segment that includes neoadjuvant chemotherapy and adjuvant chemotherapy accounted for the major shares of the bladder cancer therapeutics market during 2016. This is mainly due to the increase in incidences of bladder cancer and the growing adoption of chemotherapy in the developing countries.
Based on the bladder cancer therapeutics market growth analysis, the Americas will be the major revenue contributor to the market during 2016. Though the bladder cancer therapeutics market in the Americas will grow at a lesser rate than the other regions, this region will continue its market dominance throughout the predicted period due to factors such as the increasing focus of vendors to develop targeted therapies and the presence of major vendors such as Pfizer and Merck.
Technavio also offers customization on reports based on specific client requirement.
PART 01: Executive summary
PART 02: Scope of the report
PART 03: Research Methodology
PART 04: Introduction
PART 05: Key clinical trials
PART 06: Market landscape
PART 07: Market segmentation by therapy
PART 08: Geographical segmentation
PART 09: Decision framework
PART 10: Drivers and challenges
PART 11: Market trends
PART 12: Vendor landscape
PART 13: Key vendor analysis
PART 14: Appendix
Tags: liver cancer, cancer treatment, cancer test, cancer surgery, urology devices industry size, urology devices top companies,
Get lifetime access to our
Technavio Insights
Quick Report Overview:
Cookie Policy
The Site uses cookies to record users' preferences in relation to the functionality of accessibility. We, our Affiliates, and our Vendors may store and access cookies on a device, and process personal data including unique identifiers sent by a device, to personalise content, tailor, and report on advertising and to analyse our traffic. By clicking “I’m fine with this”, you are allowing the use of these cookies. Please refer to the help guide of your browser for further information on cookies, including how to disable them. Review our Privacy & Cookie Notice.